This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Rotator Interval and Intra-articular Corticosteroid Injection for Frozen Shoulder

This study has been completed.
Information provided by (Responsible Party):
Tore Prestegaard, Sykehuset i Vestfold HF Identifier:
First received: February 8, 2009
Last updated: November 24, 2013
Last verified: November 2013

The purpose of this study is to compare ultrasound guided capsular corticosteroid injection into the rotator interval/anterior capsule and the GH joint with ultrasound guided corticosteroid injection into the GH joint only. Both methods will be compared with placebo injections.

Primary outcome measure: pain reduction at week 6 Secondary outcome measures: improvement of function (SPADI, Life quality, ROM).

0-hypothesis: no difference between the methods.

The investigators want to find out if the clinical effect of the combined capsular and intra-articular injections are better than placebo and better that intra-articular injections

Condition Intervention
Adhesive Capsulitis Drug: Triamcinolone hexacetonide

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Rotator Interval and Intra-articular Corticosteroid Injection for Adhesive Capsulitis (Frozen Shoulder): a Randomised, Double Blind, Placebo Controlled Trial

Resource links provided by NLM:

Further study details as provided by Tore Prestegaard, Sykehuset i Vestfold HF:

Primary Outcome Measures:
  • Pain reduction [ Time Frame: 2-3 years ]

Secondary Outcome Measures:
  • Function (ROM, SPADI), Life quality [ Time Frame: 2-3 years ]

Enrollment: 122
Study Start Date: February 2009
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 capsular & intra-articular
corticosteroid injection (Triamcinolone) in capsule/rotator interval and intra-articular
Drug: Triamcinolone hexacetonide
1 ml (20 mg) + 6 ml Lidocaine 10 mg/ml
Active Comparator: 2 intra-articular
corticosteroid injection (Triamcinolone) intra-articular placebo injection (Lidocaine) in capsule
Drug: Triamcinolone hexacetonide
1 ml (20 mg) + 6 ml Lidocaine 10 mg/ml
Placebo Comparator: 3 placebo
placebo injections (Lidocaine) in capsule and intra-articular
Drug: Triamcinolone hexacetonide
20 mg

Detailed Description:
3 groups, 50 patients in each, follow-up visits after 3, 6, 12 and 26 weeks.

Ages Eligible for Study:   25 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pain and stiffness in one shoulder 1 - 6 months
  • Restriction of passive ROM; >= 30 degrees in two or more planes compared to other shoulder

Exclusion Criteria:

  • Systemic inflammatory disease
  • Corticosteroid treatment last 3 months
  • Poorly controlled Diabetes mellitus
  • Pregnancy
  • Contraindications/allergy to corticosteroids and/or Lidocaine
  • Severe infections
  • Osteoarthritis of the shoulder
  • Fractures of the shoulder
  • Rotator cuff pathology causing pain or disability
  • Fibromyalgia
  • Not able to understand Norwegian
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00840229

Vestfold Hospitalt Trust, Clinic Physical Medicine and Rehabilitation
Stavern, Norway, 3294
Sponsors and Collaborators
Oslo University Hospital
Principal Investigator: Tore A Prestgaard, MD The Hospital of Vestfold
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Tore Prestegaard, MD, consultant physician, Sykehuset i Vestfold HF Identifier: NCT00840229     History of Changes
Other Study ID Numbers: S-08546
REK ( Registry Identifier: S-08546 )
Interne tjenester ( Other Identifier )
IT-avdelingen ( Other Identifier: 2008/5000 )
Rikshospitalet HF ( Other Identifier )
Study First Received: February 8, 2009
Last Updated: November 24, 2013

Keywords provided by Tore Prestegaard, Sykehuset i Vestfold HF:
adhesive capsulitis

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Triamcinolone hexacetonide
Triamcinolone Acetonide
Triamcinolone diacetate
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunosuppressive Agents
Immunologic Factors
Enzyme Inhibitors processed this record on August 23, 2017